Regeneron's (REGN) Dupixent (dupilumab) approved in the US as the first and only medicine for Allergic Fungal Rhinosinusitis
Importance
Level 1
#REGENERON PHARMACEUTICALS INC#REGN.US#EQUITIES#EU SESSION#US SESSION#BIOTECHNOLOGY#BIOTECHNOLOGY (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#S&P 500 INDEX#NASDAQ 100 INDEX#REGN#US EQUITIES